Skip to content

Alzheimer’s Progression Slowed by Drug in Major Trial

  • Biogen shares soar as much as 43% in New York; Eisai gains 17%
  • Lilly, Roche also rise; they have similar drugs in development
Updated on

Biogen Inc. and partner Eisai Co. surged and led other drugmakers’ shares higher amid optimism about their breakthrough trial results on Alzheimer’s disease. 

The two partners said their experimental drug lecanemab significantly slowed the debilitating brain disease, making it the first medicine to blunt progression of the most common form of dementia in a large definitive study.